Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Filgrastim | Research

Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation

Authors: J. Heyn, S. Bräuninger, M. Dimova-Dobreva, N. Mathieson, N. Koptelova, A. Kolpakova, C. Seidl, P. Reinhardt, C. Tsamadou, H. Schrezenmeier, R. Nakov, E. Seifried, H. Bonig

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Safety, tolerability and efficacy of granulocyte colony-stimulating factor (G-CSF) for mobilization of hematopoietic stem and progenitor cells (HSPCs) from healthy donors have been conclusively demonstrated. This explicitly includes, albeit for smaller cohorts and shorter observation periods, biosimilar G-CSFs. HSPC donation is non-remunerated, its sole reward being “warm glow”, hence harm to donors must be avoided with maximal certitude. To ascertain, therefore, long-term physical and mental health effects of HSPC donation, a cohort of G-CSF mobilized donors was followed longitudinally.

Methods

We enrolled 245 healthy volunteers in this bi-centric long-term surveillance study. 244 healthy volunteers began mobilization with twice-daily Sandoz biosimilar filgrastim and 242 underwent apheresis after G-CSF mobilization. Physical and mental health were followed up over a period of 5-years using the validated SF-12 health questionnaire.

Results

Baseline physical and mental health of HSPC donors was markedly better than in a healthy reference population matched for ethnicity, sex and age. Physical, but not mental health was sharply diminished at the time of apheresis, likely due to side effects of biosimilar G-CSF, however had returned to pre-apheresis values by the next follow-up appointment after 6 months. Physical and mental health slightly deteriorated over time with kinetics reflecting the known effects of aging. Hence, superior physical and mental health compared to the general healthy non-donor population was maintained over time.

Conclusions

HSPC donors are of better overall physical and mental health than the average healthy non-donor. Superior well-being is maintained over time, supporting the favorable risk–benefit assessment of volunteer HSPC donation.
Trial registration National Clinical Trial NCT01766934
Appendix
Available only for authorised users
Literature
1.
go back to reference Melve GK, Ersvaer E, Eide GE, Kristoffersen EK, Bruserud O. Peripheral blood stem cell mobilization in healthy donors by granulocyte colony-stimulating factor causes preferential mobilization of lymphocyte subsets. Front Immunol. 2018;9:845.CrossRef Melve GK, Ersvaer E, Eide GE, Kristoffersen EK, Bruserud O. Peripheral blood stem cell mobilization in healthy donors by granulocyte colony-stimulating factor causes preferential mobilization of lymphocyte subsets. Front Immunol. 2018;9:845.CrossRef
2.
go back to reference Bonig H, Becker PS, Schwebig A, Turner M. Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid? Transfusion. 2015;55:430–9.CrossRef Bonig H, Becker PS, Schwebig A, Turner M. Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid? Transfusion. 2015;55:430–9.CrossRef
3.
go back to reference Pahnke S, Egeland T, Halter J, Hagglund H, Shaw BE, Woolfrey AE, Szer J. Working Group medical of the world marrow donor a: current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant. 2019;54:858–66.CrossRef Pahnke S, Egeland T, Halter J, Hagglund H, Shaw BE, Woolfrey AE, Szer J. Working Group medical of the world marrow donor a: current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant. 2019;54:858–66.CrossRef
4.
go back to reference Kabir ER, Moreino SS, Sharif Siam MK. The breakthrough of biosimilars: a twist in the narrative of biological therapy. Biomolecules. 2019;9:410.CrossRef Kabir ER, Moreino SS, Sharif Siam MK. The breakthrough of biosimilars: a twist in the narrative of biological therapy. Biomolecules. 2019;9:410.CrossRef
5.
go back to reference Becker P, Schwebig A, Brauninger S, Bialleck H, Luxembourg B, Schulz M, Tsamadou C, Wiesneth M, Reinhardt P, Mytilineos J, et al. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance. Transfusion. 2016;56:3055–64.CrossRef Becker P, Schwebig A, Brauninger S, Bialleck H, Luxembourg B, Schulz M, Tsamadou C, Wiesneth M, Reinhardt P, Mytilineos J, et al. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance. Transfusion. 2016;56:3055–64.CrossRef
6.
go back to reference Schellekens H. Assessing the bioequivalence of biosimilars: the retacrit case. Drug Discov Today. 2009;14:495–9.CrossRef Schellekens H. Assessing the bioequivalence of biosimilars: the retacrit case. Drug Discov Today. 2009;14:495–9.CrossRef
7.
go back to reference Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–6.CrossRef Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–6.CrossRef
8.
go back to reference Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, Cortes L, Zander AR. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol. 2000;111:761–5.PubMed Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, Cortes L, Zander AR. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol. 2000;111:761–5.PubMed
9.
go back to reference Shaw BE, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant. 2015;50:334–40.CrossRef Shaw BE, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant. 2015;50:334–40.CrossRef
10.
go back to reference Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111:1767–72.CrossRef Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111:1767–72.CrossRef
11.
go back to reference Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C, Seifried E, Tonn T, Bonig H. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang. 2013;104:46–54.CrossRef Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C, Seifried E, Tonn T, Bonig H. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang. 2013;104:46–54.CrossRef
12.
go back to reference Brauninger S, Thorausch K, Luxembourg B, Schulz M, Chow KU, Seifried E, Bonig H. Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation. Bone Marrow Transplant. 2014;49:1419–25.CrossRef Brauninger S, Thorausch K, Luxembourg B, Schulz M, Chow KU, Seifried E, Bonig H. Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation. Bone Marrow Transplant. 2014;49:1419–25.CrossRef
13.
go back to reference National Medical Council. Guidelines for collection of blood and blood components and for the application of blood products (hemotherapy). Köln: Deutscher Ärzteverlag; 2008. National Medical Council. Guidelines for collection of blood and blood components and for the application of blood products (hemotherapy). Köln: Deutscher Ärzteverlag; 2008.
14.
go back to reference Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, Tonn T. Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD stem cell enumeration kit. Cytotherapy. 2011;13:449–58.CrossRef Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, Tonn T. Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD stem cell enumeration kit. Cytotherapy. 2011;13:449–58.CrossRef
15.
go back to reference Bullinger M, Kirchberge I. SF-36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe-Verlag GmbH & Co.KG; 1998. Bullinger M, Kirchberge I. SF-36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe-Verlag GmbH & Co.KG; 1998.
16.
go back to reference Wirtz M, Morfeld M, Glaesmer H, Braehler E. Normierung des SF-12 Version 2.0 zur Messung der gesundheitsbezogenen Lebensqualität in einer deutschen bevölkerungsrepräsentativen Stichprobe. Diagnostica. 2018;64:215–26.CrossRef Wirtz M, Morfeld M, Glaesmer H, Braehler E. Normierung des SF-12 Version 2.0 zur Messung der gesundheitsbezogenen Lebensqualität in einer deutschen bevölkerungsrepräsentativen Stichprobe. Diagnostica. 2018;64:215–26.CrossRef
17.
go back to reference Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 2010;115:5131–6.CrossRef Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 2010;115:5131–6.CrossRef
18.
go back to reference Jabagi MJ, Vey N, Goncalves A, Le Tri T, Zureik M, Dray-Spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: a nationwide population-based cohort. Int J Cancer. 2021;148:375–84.CrossRef Jabagi MJ, Vey N, Goncalves A, Le Tri T, Zureik M, Dray-Spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: a nationwide population-based cohort. Int J Cancer. 2021;148:375–84.CrossRef
19.
go back to reference Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113:3604–11.CrossRef Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113:3604–11.CrossRef
20.
go back to reference Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, Rutt C, Ehninger G. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114:3757–63.CrossRef Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, Rutt C, Ehninger G. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114:3757–63.CrossRef
21.
go back to reference Galenkamp H, Stronks K, Mokkink LB, Derks EM: Measurement invariance of the SF-12 among different demographic groups: The HELIUS study. PLoS One 2018, 13:e0203483. Galenkamp H, Stronks K, Mokkink LB, Derks EM: Measurement invariance of the SF-12 among different demographic groups: The HELIUS study. PLoS One 2018, 13:e0203483.
22.
go back to reference Kuehne A, Huschke S, Bullinger M. Subjective health of undocumented migrants in Germany—a mixed methods approach. BMC Public Health. 2015;15:926.CrossRef Kuehne A, Huschke S, Bullinger M. Subjective health of undocumented migrants in Germany—a mixed methods approach. BMC Public Health. 2015;15:926.CrossRef
23.
go back to reference Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171–8.CrossRef Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171–8.CrossRef
24.
go back to reference Atsma F, Veldhuizen I, Verbeek A, de Kort W, de Vegt F. Healthy donor effect: its magnitude in health research among blood donors. Transfusion. 2011;51:1820–8.CrossRef Atsma F, Veldhuizen I, Verbeek A, de Kort W, de Vegt F. Healthy donor effect: its magnitude in health research among blood donors. Transfusion. 2011;51:1820–8.CrossRef
25.
go back to reference Glynn SA, Kleinman SH, Schreiber GB, Zuck T, Combs SM, Bethel J, Garratty G, Williams AE. Retrovirus Epidemiology Donor S: Motivations to donate blood: demographic comparisons. Transfusion. 2002;42:216–25.CrossRef Glynn SA, Kleinman SH, Schreiber GB, Zuck T, Combs SM, Bethel J, Garratty G, Williams AE. Retrovirus Epidemiology Donor S: Motivations to donate blood: demographic comparisons. Transfusion. 2002;42:216–25.CrossRef
26.
go back to reference Hinrichs A, Picker SM, Schneider A, Lefering R, Neugebauer EA, Gathof BS. Effect of blood donation on well-being of blood donors. Transfus Med. 2008;18:40–8.CrossRef Hinrichs A, Picker SM, Schneider A, Lefering R, Neugebauer EA, Gathof BS. Effect of blood donation on well-being of blood donors. Transfus Med. 2008;18:40–8.CrossRef
Metadata
Title
Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation
Authors
J. Heyn
S. Bräuninger
M. Dimova-Dobreva
N. Mathieson
N. Koptelova
A. Kolpakova
C. Seidl
P. Reinhardt
C. Tsamadou
H. Schrezenmeier
R. Nakov
E. Seifried
H. Bonig
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03322-w

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine